Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 15/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 14/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.55 |
| ▸ | DRD2 | P14416 | 6/20 | 0.53 |
| ▸ | DRD3 | P35462 | 6/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD5 | P21918 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1026339 | 0.85 | TAAR1 (0.47) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL5343307 | 0.84 | MEN1 (0.53) | OPRK1OPRM1OPRD1MEN1HTT | |
| SCHEMBL21247482 | 0.84 | KMT2A (0.63) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1704199 | 0.84 | TAAR1 (0.55) | OPRD1MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1205533 | 0.84 | MAOA (0.49) | OPRK1OPRM1OPRD1MEN1HTT | |
| SCHEMBL1029848 | 0.81 | AOC3 (0.55) | MEN1KMT2A | |
| SCHEMBL4147783 | 0.81 | ESRRG (0.49) | OPRK1OPRM1OPRD1MEN1HTT | |
| SCHEMBL320435 | 0.80 | FFAR1 (0.44) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL3401759 | 0.80 | OPRK1 (0.60) | OPRK1OPRM1OPRD1DRD2DRD3 | |
| SCHEMBL1204376 | 0.79 | ALDH1A1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518050-B2 | Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity | ALMIRALL, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| US-7612084-B2 | Amine derivatives for the treatment of asthma and COPD | PFIZER INC (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090253739-A1 | Amine Derivatives | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265303-A1 | Amine derivatives | HNMT, HRH4, CMA1 | OPRK1 343/4885OPRM1 948/4885OPRD1 690/4885 |
| US-20090253739-A1 | Amine Derivatives | HNMT, HRH4, CMA1 | OPRK1 343/4885OPRM1 948/4885OPRD1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.